The MSc in Biotherapeutics and Business educates students on the practical uses of molecular advances in the discovery of proteins and other biomolecular drug candidates and their development into biotherapeutics. It will provide students with a comprehensive understanding of the development of biotherapeutics, beginning with pre-clinical modelling and target identification together with antibody engineering, biochemical and biophysical characterisation, and development issues for bioprocessing. Systems biology of biotechnological processes and approaches to the analysis of proteomicsbased discovery data will be covered in detail, together with mathematical modelling, bioinformatics analysis and data integration strategies. Regulatory issues, and innovation and commercialisation strategies, will also be covered. Mammalian cell culture and bioprocess laboratory structure will be comprehensively covered in addition to novel approaches to therapeutic development. You will also receive a comprehensive business education. You will learn to identify and solve business problems in local and international settings, enhance your communication and leadership skills, and improve your ability for independent thinking and developing creative solutions.
The programme is the result of a close collaboration between the UCD School of Biomolecular and Biomedical Science and the UCD Michael Smurﬁt Graduate School of Business, which is Ireland’s leading business school.
Course Content and Structure
90 credits 60 credits 30 credits taught masters taught modules project modules The structure of the programme is as follows: Semester 1 • Professional Career Development • Management & Org. Behaviour • Corporate Accounting & Finance • Business of Biotechnology & Science • Biotherapeutic Pipeline I • Recombinant DNA Technology • Biomedical Diagnostics • High Content Screening Microscopy • Pharmacology & Drug Development Semester 2 • Professional Career Development • Biotherapeutic Pipeline II • Systems Biology in Drug Development • Bioprocessing Laboratory • Emerging Issues in Biotechnology • Regulatory Affairs • Microbial & Animal Cell Products Semester 3 • Valuation and Commercialisation of Biotherapeutics • Biotherapeutics Case Study Modules and topics shown are subject to change and are not guaranteed by UCD.
This advanced graduate degree in Biotherapeutics and Business has been developed in consultation with employers and therefore will be recognised and valued by them. A key feature is the opportunity to carry out a business development plan, which will allow graduates to develop connections with prospective employers, thereby enhancing chances of employment on graduation. Prospective employers include: Abbott; Allergan; Amgen; Baxter Healthcare; Eli Lilly and Co.; Dignity Sciences; GlaxoSmithKline; Icon Clinical Research; ImmunoGen Inc.; Janssen Pharmaceutical Ltd.; Johnson & Johnson Ltd.; Merck Sharp & Dohme; Quintiles; Quest International; Sandoz; Seroba Kernel.
Facilities and Resources
Students on this programme will benefi t from the use of a research skills laboratory in the prestigious UCD Conway Institute, as well as state-of-the-art teaching and laboratory facilities in the new O’Brien Centre for Science.
• This programme is intended for applicants who have an upper second class honoursdegree, or the international equivalent, in a biological or chemical science.• This includes a BSc in Biotechnology, Biochemistry, Microbiology, Genetics,Neuroscience, Physiology, Pharmacology, Medicinal Chemistry or an equivalentqualifi cation.• Applicants whose fi rst language is not English must also demonstrateEnglish language profi ciency of IELTS 6.5 (no band less than 6.0 in eachelement), or equivalent.
Recipient: University College Dublin
Insert previous message below for editing?
You haven’t included a message. Providing a specific message means universities will take your enquiry more seriously and helps them provide the information you need. Why not add a message here